Please login to the form below

Not currently logged in

Shionogi Europe and NHS England agree on antibiotic subscription model

The antibiotic Fetcroja, along with Zavicefta, will be made available as an option to help address antimicrobial resistance


Shionogi Europe has entered into an agreement with NHS England to initiate an innovative subscription payment model for the reimbursement of Fetroja (cefiderocol) in England.

As part of the model, companies will be paid a fixed amount for antimicrobials based on a health technology assessment of their value to the NHS, as opposed to the volumes used. Pull incentives like this payment model will help to encourage the research and development of critically needed antibiotics.

The deal comes after the National Institute for Health and Care Excellence’s (NICE) draft guidance recommending Fetcroja, issued in April 2022, for the treatment of severe multidrug-resistant aerobic Gram-negative bacterial infections.

The guidance also specified that the drug should be restricted for use as risk-based empiric treatment, or in cases of difficult to treat resistant infections, where few alternative treatment options exist.

Fetcroja is one of two antimicrobial products – the other being Zavicefta (ceftazidime-avibactam), manufactured by Pfizer – to be selected and made available under the scheme run by NICE and NHS England. Both drugs address vital disease areas of unmet need, in the UK and internationally, for treating serious infections including blood stream infection (BSI), sepsis and hospital- or ventilator-acquired pneumonia.

“We are delighted that NICE and NHS England have recognised the important role of Cefiderocol as an option to treat some of the most serious multidrug-resistant infections and its value to healthcare systems and society,” said Mark Hill, senior vice president, global head of market access, Shionogi.

He added: “Antimicrobial resistance is becoming a significant global threat and subscription-style schemes like this help to ensure that antibiotics are used to benefit patients who need them and according to effective stewardship principles to limit the potential development of resistance.”

NICE considered the potential long-term population benefits of Fetcroja, including the ‘insurance/diversity’ value of having additional antimicrobial treatments available for the future, and the ‘enablement’ value linked with the continued ability to provide other healthcare – such as chemotherapy and surgical procedures – that might otherwise be compromised by increasing antimicrobial resistance (AMR).

AMR is a serious health burden, resulting in more than 700,000 deaths worldwide and 5,000 deaths each year in England from infections with multidrug-resistant bacteria. If the issue is left unaddressed, AMR is predicted to result in ten million deaths every year globally by 2050.

Article by
Fleur Jeffries

16th June 2022

From: Regulatory, Healthcare



Subscribe to our email news alerts

Featured jobs


Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

Virtual MSL/Sales training programs and events
Top 10 ways to leverage the Impetus InSite Platform® for internal MSL/Sales training programs and events...
6 trends shaping the future of personalized medicine
Senior Consultant Leah Carlisle explores the key trends discussed at the 16th annual Personalized Medicine Conference, providing expert analysis and key recommendations for biopharmaceutical innovators....
Omnichannel strategies to revolutionize the healthcare professional experience
Fishawack Health’s omnichannel experts unite to reveal how medical and commercial teams can build more meaningful experiences for healthcare professionals. They discuss the opportunities of omnichannel and explore how the...